• Explore /
  • Videos & Slides
  • / PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

Abstract Video & Slides

Presenter

null

Deborah Schrag, MD, FASCO, MPH

Memorial Sloan Kettering Cancer Center

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2023 ASCO Annual Meeting

Session Type

Plenary Session

Session Title

Plenary Session

Track

Special Sessions,Central Nervous System Tumors,Gastrointestinal Cancer—Colorectal and Anal,Lung Cancer,Hematologic Malignancies

Sub Track

Colorectal Cancer–Local-Regional Disease

Clinical Trial Registration Number

NCT01515787

Citation

J Clin Oncol 41, 2023 (suppl 17; abstr LBA2)

DOI

10.1200/JCO.2023.41.17_suppl.LBA2

Abstract #

LBA2

Abstract Disclosures

Similar Videos & Slides

Speaker: Deborah Schrag

Speaker: David Sebag-Montefiore, MD

Speaker: Jens Hoeppner, MD, FAChirg

Speaker: ZiQiang Wang, MD, PhyD